FTXH icon

First Trust Nasdaq Pharmaceuticals ETF
FTXH

28.25 USD
+0.24
0.86%
At close Mar 5, 4:00 PM EST
1 day
0.86%
5 days
1.29%
1 month
0.86%
3 months
0.61%
6 months
-2.42%
Year to date
4.51%
1 year
1.88%
5 years
29.35%
10 years
38.21%
0
Funds holding %
of 7,351 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

5% less funds holding

Funds holding: 22 [Q3] → 21 (-1) [Q4]

4.66% less ownership

Funds ownership: 43.5% [Q3] → 38.83% (-4.66%) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

24% less capital invested

Capital invested by funds: $7.55M [Q3] → $5.77M (-$1.77M) [Q4]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for FTXH.

See Analyst Rankings

Financial journalist opinion

Neutral
Seeking Alpha
1 week ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Positive
Zacks Investment Research
6 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Pharma ETFs in Focus Post Solid Q2 Earnings
Positive
Zacks Investment Research
9 months ago
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Positive
Zacks Investment Research
10 months ago
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
Neutral
Zacks Investment Research
1 year ago
A Look at Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
See News Rankings
Charts implemented using Lightweight Charts™